Kira Launches with $46 Million to Combat Complement-Mediated Diseases
On November 12th, Kira Pharmaceuticals emerged from stealth mode, announcing $46 million ($18 million Series A and $28 million Series B) in investments and the appointment of Frederick Beddingfield, MD, …
Read More